Portable Point-of-Care Type 2 Diabetes Decision Analysis

便携式护理点 2 型糖尿病决策分析

• 批准号: 6999193
• 负责人: Harry Jerome Smolen
• 金额: $ 41.36万
• 依托单位: MEDICAL DECISION MODELING, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6999193
• 关键词: automated medical record system; clinical research; comorbidity; computer assisted medical decision making; computer program /software; computer system design /evaluation; health care model; human subject; medical complication; model design /development; noninsulin dependent diabetes mellitus; outcomes research; patient care management; therapy compliance

DESCRIPTION (provided by applicant): The broad, long term objective of this project is to research, develop, and commercialize evidence-based medical decision models. The models will enhance public health by improving the treatment decisions of payers, providers, and patients when considering competing courses of treatment for conditions that are common, costly, and have controversy as to which treatment is appropriate. The specific aims of this Phase II project are to: (1) Develop a commercializable type 2 diabetes model that can be used by providers to assess competing strategies for the management of type 2 diabetes, its complications, and its comorbidities; (2) Design, implement, and evaluate software technologies that will allow the diabetes model to execute in a standalone fashion on portable computing platforms; (3) Integrate the Phase II diabetes decision model, an existing electronic medical record (EMR) system, and the American Diabetes Association care guidelines to demonstrate to clinicians the benefits of complying with the care guidelines at the patient-specific level; (4) Evaluate and quantify any changes in clinician care guideline compliance, resulting from providing clinicians expected patient-specific outcomes data at the point of care. MDM's Phase II diabetes model will be based on an NIH- and CDC-funded model developed at the University of Michigan, MDM's Phase I diabetes model, and an MDM model of hypertension treatment. The existing hypertension model is based upon published studies from peer-reviewed medical journals and examines the effects of treatment with ACE inhibitors and Angiotensin II receptor blockers. In Phase II MDM will develop and evaluate a product with the potential to improve health outcomes and reduce overall costs for patients with diabetes by improving the knowledge, awareness, and compliance of appropriate courses of care. The technological innovation in this project stems from the innovative software technologies that will expand the distribution of medical decision models and the world's interaction with them. MDM's project goal promotes the National Institutes of Health's stated mission of "fostering communication of medical and health sciences information".

描述（由申请人提供）： 该项目的长期目标是研究、开发和商业化循证医学决策模型。这些模型将通过改善支付者、提供者和患者在考虑针对常见、昂贵且对哪种治疗方法合适存在争议的疾病的竞争性治疗过程时的治疗决策来增强公共卫生。该II期项目的具体目标是：（1）开发可商业化的2型糖尿病模型，供供应商用于评估管理2型糖尿病、其并发症及其合并症的竞争策略;（2）设计、实施和评估软件技术，使糖尿病模型能够在便携式计算平台上以独立方式执行;（3）整合II期糖尿病决策模型、现有的电子病历（EMR）系统和美国糖尿病协会护理指南，以向临床医生证明在患者特定水平上遵守护理指南的益处;（4）评估和量化临床医生护理指南依从性的任何变化，这是由于在护理点为临床医生提供预期的患者特异性结果数据。MDM的II期糖尿病模型将基于密歇根大学开发的NIH和CDC资助的模型，MDM的I期糖尿病模型和MDM高血压治疗模型。现有的高血压模型是基于同行评审的医学期刊发表的研究，并检查了ACE抑制剂和血管紧张素II受体阻滞剂治疗的效果。在II期，MDM将开发和评估一种产品，该产品有可能通过提高适当护理课程的知识、意识和依从性来改善糖尿病患者的健康结局并降低其总体成本。该项目的技术创新源于创新的软件技术，这些技术将扩大医疗决策模型的分布以及世界与它们的互动。MDM的项目目标是促进国立卫生研究院的“促进医学和健康科学信息的交流”的使命。